Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Parkinson's Disease

  Free Subscription


11.05.2020

1 Ann Intern Med
1 Drugs
1 J Neural Transm (Vienna)
2 J Neurol Neurosurg Psychiatry
3 Mov Disord
2 Neurology
2 PLoS One
1 Rev Neurol (Paris)


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Intern Med

  1. LOGE RV
    Last Call to Wisdom.
    Ann Intern Med. 2020;172:218-219.
    PubMed        


    Drugs

  2. VIJIARATNAM N, Foltynie T
    Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson's Disease.
    Drugs. 2020 May 7. pii: 10.1007/s40265-020-01310.
    PubMed         Abstract available


    J Neural Transm (Vienna)

  3. RIZOS A, Sauerbier A, Falup-Pecurariu C, Odin P, et al
    Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson's disease patients: an European multicentre survey.
    J Neural Transm (Vienna). 2020 May 5. pii: 10.1007/s00702-020-02168.
    PubMed         Abstract available


    J Neurol Neurosurg Psychiatry

  4. JENKINS PO, Roussakis AA, De Simoni S, Bourke N, et al
    Distinct dopaminergic abnormalities in traumatic brain injury and Parkinson's disease.
    J Neurol Neurosurg Psychiatry. 2020 May 7. pii: jnnp-2019-321759.
    PubMed         Abstract available

  5. JOST ST, Sauerbier A, Visser-Vandewalle V, Ashkan K, et al
    A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up.
    J Neurol Neurosurg Psychiatry. 2020 May 5. pii: jnnp-2019-322614.
    PubMed         Abstract available


    Mov Disord

  6. FAN SP, Lee NC, Lin CH
    Novel Phenotype of 6p25 Deletion Syndrome Presenting Juvenile Parkinsonism and Brain Calcification.
    Mov Disord. 2020 May 5. doi: 10.1002/mds.28079.
    PubMed         Abstract available

  7. UCHIDA Y, Kan H, Sakurai K, Inui S, et al
    Magnetic Susceptibility Associates with Dopaminergic Deficits and Cognition in Parkinson's Disease.
    Mov Disord. 2020 May 5. doi: 10.1002/mds.28077.
    PubMed         Abstract available

  8. SCHNEIDER SA, Alcalay RN
    Precision Medicine for Parkinson's Disease: Ambroxol for Glucocerebrosidase-Associated Parkinson's Disease, First Trial Completed.
    Mov Disord. 2020 May 7. doi: 10.1002/mds.28072.
    PubMed        


    Neurology

  9. MAPPIN-KASIRER B, Pan H, Lewington S, Kizza J, et al
    Tobacco smoking and the risk of Parkinson disease: A 65-year follow-up of 30,000 male British doctors.
    Neurology. 2020 May 5. pii: WNL.0000000000009437.
    PubMed         Abstract available

  10. CHENG Y, Wang YJ
    Tobacco smoking and the reduced risk of Parkinson disease: A puzzle of 60 years.
    Neurology. 2020 May 5. pii: WNL.0000000000009431.
    PubMed        


    PLoS One

  11. SANCHEZ-LANZAS R, Castano JG
    Correction: Inhibitors of lysosomal function or serum starvation in control or LAMP2 deficient cells do not modify the cellular levels of Parkinson disease-associated DJ-1/PARK 7 protein.
    PLoS One. 2020;15:e0233091.
    PubMed         Abstract available

  12. GRUBER MT, Witte OW, Grosskreutz J, Prell T, et al
    Association between malnutrition, clinical parameters and health-related quality of life in elderly hospitalized patients with Parkinson's disease: A cross-sectional study.
    PLoS One. 2020;15:e0232764.
    PubMed         Abstract available


    Rev Neurol (Paris)

  13. REBAI A, Chbili C, Ben Amor S, Hassine A, et al
    Effects of glutathione S-transferase M1 and T1 deletions on Parkinson's disease risk among a North African population.
    Rev Neurol (Paris). 2020 Apr 29. pii: S0035-3787(20)30508.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: